Retention of CD34(+) CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors

por Minami, Y, Abe, A, Minami, M, Kitamura, K, Hiraga, J, Mizuno, S, Ymamoto, K, Sawa, M, Inagaki, Y, Miyamura, K, Naoe, T
Publicado 2012

P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL

por Yamazaki, H., Lee, J. W., Jang, J. H., Sawa, M., Kizaki, M., Tomiyama, Y., Nagafuji, K., Usuki, K., Gau, J.-P., Morita, Y., Tang, J.-L., Chang, H., Noshiro, M., Matsuda, A., Ozawa, K., Mitani, K., Kanda, Y., Nakao, S.
Publicado 2022